Page 421 - Read Online

Droste et al. J Cancer Metastasis Treat 2023;9:2 https://dx.doi.org/10.20517/2394-4722.2022.94 Page 17 of 22

2. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci USA 2001;98:10869-74. DOI PubMed PMC
3. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001;28:291-304. DOI PubMed
4. O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 2016;13:417-30. DOI
PubMed
5. Li Z, Zou W, Zhang J, et al. Mechanisms of CDK4/6 inhibitor resistance in luminal breast cancer. Front Pharmacol 2020;11:580251.
DOI PubMed PMC
6. Martin M, Zielinski C, Ruiz-Borrego M, et al. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal
receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III
randomised controlled trial-PEARL. Ann Oncol 2021;32:488-99. DOI PubMed
7. Park YH, Kim TY, Kim GM, et al. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in
premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre,
open-label, randomised, phase 2 trial. Lancet Oncol 2019;20:1750-9. DOI PubMed
8. Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole
alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a
randomised phase 2 study. Lancet Oncol 2015;16:25-35. DOI PubMed
9. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925-36. DOI
10. Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive,
advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19:904-15. DOI PubMed
11. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J
Med 2022;386:942-50. DOI PubMed
12. Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced
breast cancer. NPJ Breast Cancer 2019;5:5. DOI PubMed PMC
13. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J
Med 2016;375:1738-48. DOI
14. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:307-
16. DOI
15. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med
2020;382:514-24. DOI
16. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol
2017;35:3638-46. DOI
17. Li J, Huo X, Zhao F, et al. Association of cyclin-dependent kinases 4 and 6 inhibitors with survival in patients with hormone
receptor-positive metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw Open 2020;3:e2020312. DOI
PubMed PMC
18. Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus
letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol
2018;29:1541-7. DOI
19. Seidman AD, Bordeleau L, Fehrenbacher L, et al. National cancer institute breast cancer steering committee working group report on
meaningful and appropriate end points for clinical trials in metastatic breast cancer. J Clin Oncol 2018;36:3259-68. DOI PubMed
PMC
20. Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal
growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat 2019;174:719-29. DOI
PubMed PMC
21. Finn RS, Rugo HS, Dieras VC, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus
letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast
cancer (ER+/HER2- ABC): analyses from PALOMA-2. JCO 2022;40:LBA1003. DOI
22. Pfizer. Pfizer announces overall survival results from phase 3 PALOMA-2 trial of IBRANCE® (palbociclib) for the first-line
treatment of ER+, HER2- metastatic breast cancer. Available from: www.pfizer.com/news/press-release/press-release-detail/pfizer-
announces-overall-survival-results-phase-3-paloma-2 [Last accessed on 16 Feb 2023].
23. Helwick, caroline. paloma-2: no overall survival benefit reported with palbociclib/letrozole in Advanced breast cancer. The ASCO
post. Available from: https://ascopost.com/issues/august-10-2022/no-overall-survival-benefit-reported-with-palbociclibletrozole-in-
advanced-breast-cancer/ [Last accessed on 16 Feb 2023].
24. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med
2018;379:1926-36. DOI
25. Cristofanilli M, Rugo HS, Im S, et al. Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone
receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): updated
analyses from PALOMA-3. JCO 2021;39:1000. DOI
26. Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive,
ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol